“So on etrasimod, keep in mind that this product, we still anticipate to be over $1 billion in peak sales.”

In context

“y as a fourth generation and will do that successfully and fast. So that's the story and let's move to the next question, please. Operator: Next, we have a question from Trung Huynh with UBS. Trung Huynh: Trung from UBS. Two, please. So in your prepared remarks, you noted you took a $1.4 billion impairment charge associated with etrasimod. Can you add more color here? What prompted that reevaluation? And any feedback of how that launch has gone? Secondly, on Abrysvo, so can you give us some color on how your contracting has evolved in '24 versus '23? And based on that, what's your market share do you think you can capture this year versus the 35% last year? Albert Bourla: Thank you very much. Why don't you take the impairment question and then I will move to commercial? David Denton: Yes. So on etrasimod, keep in mind that this product, we still anticipate to be over $1 billion in peak sales. As you know, there are multiple indications attributed to this medicine. And financially, as you look at that medication, there were additional indications that met the financial criteria for an impairment of which we took in the quarter. Clinically, obviously, clinically, there's still some work that will be ongoing in support of the asset. So with that... Albert Bourla: Thank you very much. So Aamir, maybe etrasimod commercially, how the launch is doing and the Abrysvo? Aamir Malik: Sure. So I'll start with etrasimod or VELSIPITY as we call it. So just in terms of the product value proposition, we think this is a very promising oral option for moderate to severe UC patients. It's got strong efficacy that patients and physicians we've exposed this to. They want to start transitioning fro”